13 results on '"Christine Boissinot"'
Search Results
2. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial
- Author
-
Laurent Mandelbrot, François Kieffer, Rémi Sitta, Hélène Laurichesse-Delmas, Norbert Winer, Louis Mesnard, Alain Berrebi, Gwenaëlle Le Bouar, Jean-Paul Bory, Anne-Gaëlle Cordier, Yves Ville, Franck Perrotin, Jean-Marie Jouannic, Florence Biquard, Claude d’Ercole, Véronique Houfflin-Debarge, Isabelle Villena, Rodolphe Thiébaut, Denis Pons, C. Nourrisson, Rose-Anne Lavergne, Judith Fillaux, Corinne Assouline, Florence Robert-Gangneux, Coralie L’Ollivier, Florence Bretelle, Béatrice Guidicelli, Patricia Garcia, Anne-Gaelle Cordier, Alexandra Benachi, Christelle Vauloup-Fellous, Emmanuelle Letamendia, Marie-Elisabeth Bougnoux, Nathalie Van Langendonck, Jérôme Potin, Pierre Marty, Christelle Pomarès, Cynthia Trastour, Anne Sophie Deleplancque, Jean-Marc Costa, Marie-Thérèse Chève, Jean-Yves Col, Bernard Cimon, Y. Sterkers, Laurence Lachaud, Gilles Burlet, Martine Maréchaud, Estelle Perraud, Anne-Gaelle Grébille, Morgane Valentin, Sandrine Houzé, Sophie Omnès, Yvon Chitrit, Christine Boissinot, Hélène Yéra, Olivia Anselem, Vassilis Tsatsaris, Marie-Victoire Sénat, Florent Fuchs, Adela Angoulvant, Charles Muszynski, Anne Totet, Catherine Noël, Laurent Bidat, Tiphaine Barjat, Pierre Flori, Hervé Pelloux, Marie-Pierre Brenier-Pinchart, Catherine Thong-Vanh, Corinne Floch, Lionel Carbillon, Eric Lachassine, Aude Ricbourg, Luc Paris, Marc Dommergues, Thierry Rousseau, Frederic Dalle, Marie Laure Dardé, Véronique Aubard, Camille Olivier, Eric Verspyk, Loic Favennec, Service de gynécologie obstétrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Nord Val de Seine, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Puériculture et de Périnatalogie, Santé publique et épidémiologie des déterminants professionnels et sociaux de la santé, Epidémiologie, sciences sociales, santé publique (IFR 69), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Gynécologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Physiopathologie des Adaptations Nutritionnelles (PhAN), Institut National de la Recherche Agronomique (INRA)-Université de Nantes (UN), Gynécologie‑Obstétrique, Service de Gynécologie et Obstétrique [Rennes] = Gynaecology [Rennes], CHU Pontchaillou [Rennes], Université Paris Descartes - Paris 5 (UPD5), CHU Necker - Enfants Malades [AP-HP], Centre Hospitalier Universitaire de Reims (CHU Reims), CHRU Tours, Hôpital Bretonneau, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Gynécologie-Obstétrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Service de gynécologie-obstétrique, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle (ESCAPE), Université de Reims Champagne-Ardenne (URCA)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Université de Bordeaux (UB), Centre de recherche sur la Paléobiodiversité et les Paléoenvironnements (CR2P), Muséum national d'Histoire naturelle (MNHN)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Centre National de la Recherche Scientifique (CNRS), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Parasitologie et Mycologie, CHU Toulouse [Toulouse]-Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance Publique - Hôpitaux de Marseille (APHM), Gynépole, Aix Marseille Université (AMU)- Hôpital Nord [CHU - APHM], Service de gynécologie-obstétrique, médecine de la reproduction [Béclère], Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Division of Pediatrics and Neonatal Critical Care, FAME Department, South Paris, University Hospitals, 'A.Beclere' Medical Center-APHP, Service de Parasitologie-Mycologie-Médecine Tropicale, CHRU Bretonneau, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Anofel Cryptosporidium National Network, Institut de signalisation, biologie du développement et cancer (ISBDC), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Laboratoire de Biologie Moléculaire, Hôpital américain, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Biologie, Génétique et Pathologie des Pathogènes Eucaryotes (MIVEGEC-BioGEPPE), Pathogènes, Environnement, Santé Humaine (EPATH), Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), laboratoire parasitologie, CHU Bichat Paris, Ministère de la santé, Hôpital Louis Mourier - AP-HP [Colombes], Service de parasitologie-mycologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Service de Gynécologie et Obstétrique [Cochin], Hôpital Cochin [AP-HP], Physiopathologie et Pharmacotoxicologie Placentaire Humaine (U1139), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Gynécologie-Obstétrique [Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Service de gynécologie-obstétrique et médecine de la reproduction, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Biomécanique et Bioingénierie (BMBI), Université de Technologie de Compiègne (UTC)-Centre National de la Recherche Scientifique (CNRS), Departments of Medical Parasitology and Mycology, Centre Hospitalier René Dubos [Pontoise], Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet [Saint-Étienne] (UJM), Laboratoire de parasitologie-mycologie, CHU Grenoble, Epigenetique, Pathologie et Developpement (UMR_S_741), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de gynécologie-obstétrique [Hôpital Jean Verdier], Université Paris 13 (UP13)-Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Parasitologie - Mycologie [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Service de Gynécologie-Obstétrique, Maternité, Chirurgie Gynécologique [CHU Pitié-Salpêtrière], Centre Max Weber (CMW), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Interactions Muqueuses Agents Transmissibles (LIMA), Université de Bourgogne (UB), Service de Gynécologie-Obstétrique [CHU Limoges], CHU Limoges, CHU Tenon [AP-HP], Appareil Digestif Environnement Nutrition (ADEN ), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Bordeaux [Bordeaux], CHU Clermont-Ferrand, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional d'Orléans (CHRO), AP-HP - Hôpital Antoine Béclère [Clamart], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), PRES Université Nantes Angers Le Mans (UNAM), CHU Lille, Université de Reims Champagne-Ardenne (URCA), Hôpital Maison Blanche, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université de Nantes (UN)-Institut National de la Recherche Agronomique (INRA), Hôpital Paule de Viguier, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Reims Champagne-Ardenne (URCA), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Université Nice Sophia Antipolis (... - 2019) (UNS), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13), Service de parasitologie - mycologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service Gynécologie [CHU Toulouse], Pôle Femme-Mère-Couple [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Parasitologie et Mycologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université Jean Monnet - Saint-Étienne (UJM), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hopital Louis Mourier - AP-HP [Colombes]-Hôpitaux Universitaires Paris Nord Val de Seine, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle de Gynécologie-Obstétrique et Reproduction Humaine, CHU Clermont-Ferrand-Université de Clermont-Ferrand, Physiologie des Adaptations Nutritionnelles [UMR_A1280] (PhAN), Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Centre de recherche Médecine, Science, Santé et Société (CERMES), Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Gynécologie et Obstétrique [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes]-Hôpital Sud, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Antoine Béclère, Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], Groupe d'Etude des Interactions Hôte-Parasite (GEIHP), Institut de Recherche pour le Développement (IRD [France-Sud])-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Hopital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, Université Paris 13 (UP13)-Hôpital Jean Verdier [Bondy], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service de Gynécologie et Obstétrique [Groupe Hospitalier Pitié-Salpêtrière], CHU Pitié-Salpêtrière [APHP], and CHU Tenon [APHP]
- Subjects
0301 basic medicine ,Adult ,medicine.medical_specialty ,030106 microbiology ,Antiprotozoal Agents ,Sulfadiazine ,[SDV.MP.PRO]Life Sciences [q-bio]/Microbiology and Parasitology/Protistology ,Toxoplasmosis, Congenital ,law.invention ,03 medical and health sciences ,Folinic acid ,pyrimethamine-sulfadiazine ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Seroconversion ,Pregnancy Complications, Infectious ,ComputingMilieux_MISCELLANEOUS ,spiramycin ,prenatal diagnosis ,tolerance ,business.industry ,Spiramycin ,Obstetrics and Gynecology ,Prenatal Care ,medicine.disease ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,Toxoplasmosis ,Infectious Disease Transmission, Vertical ,3. Good health ,SISTM ,Pyrimethamine ,Treatment Outcome ,Chemoprophylaxis ,Drug Therapy, Combination ,Female ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,France ,pregnancy ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,medicine.drug ,toxoplasmosis - Abstract
International audience; Background - The efficacy of prophylaxis to prevent prenatal toxoplasmosis transmission is controversial, without any previous randomized clinical trial. In France, spiramycin is usually prescribed for maternal seroconversions. A more potent pyrimethamine + sulfadiazine regimen is used to treat congenital toxoplasmosis and is offered in some countries as prophylaxis. Objective - We sought to compare the efficacy and tolerance of pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission. Study design - This was a randomized, open-label trial in 36 French centers, comparing pyrimethamine (50 mg qd) + sulfadiazine (1 g tid) with folinic acid vs spiramycin (1 g tid) following toxoplasmosis seroconversion. Results - In all, 143 women were randomized from November 2010 through January 2014. An amniocentesis was later performed in 131 cases, with a positive Toxoplasma gondii polymerase chain reaction in 7/67 (10.4%) in the pyrimethamine + sulfadiazine group vs 13/64 (20.3%) in the spiramycin group. Cerebral ultrasound anomalies appeared in 0/73 fetuses in the pyrimethamine + sulfadiazine group, vs 6/70 in the spiramycin group (P = .01). Two of these pregnancies were terminated. Transmission rates, excluding 18 children with undefined status, were 12/65 in the pyrimethamine + sulfadiazine group (18.5%), vs 18/60 in the spiramycin group (30%, P = .147), equivalent to an odds ratio of 0.53 (95% confidence interval, 0.23-1.22) and which after adjustment tended to be stronger (P = .03 for interaction) when treatment started within 3 weeks of seroconversion (95% confidence interval, 0.00-1.63). Two women had severe rashes, both with pyrimethamine + sulfadiazine. Conclusion - There was a trend toward lower transmission with pyrimethamine + sulfadiazine, but it did not reach statistical significance, possibly for lack of statistical power because enrollment was discontinued. There were also no fetal cerebral toxoplasmosis lesions in the pyrimethamine + sulfadiazine group. These promising results encourage further research on chemoprophylaxis to prevent congenital toxoplasmosis.
- Published
- 2018
- Full Text
- View/download PDF
3. Management of Graves’ Disease during Pregnancy: The Key Role of Fetal Thyroid Gland Monitoring
- Author
-
Marie-Elisabeth Toubert, Dominique Luton, Brigitte Tébeka, Michel Polak, Paul Czernichow, Jean Guibourdenche, Marie-Hélène Schlageter, Michèle Noël, Juliane Léger, Mireille Castanet, Jean-François Oury, Isabelle Le Gac, Edith Vuillard, Christine Boissinot, and Catherine Garel
- Subjects
Adult ,endocrine system ,medicine.medical_specialty ,Goiter ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Graves' disease ,Clinical Biochemistry ,Thyroid Gland ,Biochemistry ,Thyroid function tests ,Ultrasonography, Prenatal ,Fetus ,Endocrinology ,Antithyroid Agents ,Pregnancy ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Autoantibodies ,medicine.diagnostic_test ,business.industry ,Biochemistry (medical) ,Thyroid ,Receptors, Thyrotropin ,medicine.disease ,Graves Disease ,Pregnancy Complications ,Thyroxine ,medicine.anatomical_structure ,embryonic structures ,Bone maturation ,Female ,Thyroid function ,business ,Immunoglobulins, Thyroid-Stimulating - Abstract
Background: Fetuses from mothers with Graves’ disease may experience hypothyroidism or hyperthyroidism due to transplacental transfer of antithyroid drugs (ATD) or anti-TSH receptor antibodies, respectively. Little is known about the fetal consequences. Early diagnosis is essential to successful management. We investigated a new approach to the fetal diagnosis of thyroid dysfunction and validated the usefulness of fetal thyroid ultrasonograms. Methods: Seventy-two mothers with past or present Graves’ disease and their fetuses were monitored monthly from 22 wk gestation. Fetal thyroid size and Doppler signals, and fetal bone maturation were determined on ultrasonograms, and thyroid function was evaluated at birth. Thyroid function and ATD dosage were monitored in the mothers. Results: The 31 fetuses whose mothers were anti-TSH receptor antibody negative and took no ATDs during late pregnancy had normal test results. Of the 41 other fetuses, 30 had normal test results at 32 wk, 29 were euthyroid at birth, and one had moderate hypothyroidism on cord blood tests. In the remaining 11 fetuses, goiter was visualized by ultrasonography at 32 wk, and fetal thyroid dysfunction was diagnosed and treated; there was one death, in a late referral, and 10 good outcomes with normal or slightly altered thyroid function at birth. The sensitivity and specificity of fetal thyroid ultrasound at 32 wk for the diagnosis of clinically relevant fetal thyroid dysfunction were 92 and 100%, respectively. Conclusion: In pregnant women with past or current Graves’ disease, ultrasonography of the fetal thyroid gland by an experienced ultrasonographer is an excellent diagnostic tool. This tool in conjunction with close teamwork among internists, endocrinologists, obstetricians, echographists, and pediatricians can ensure normal fetal thyroid function.
- Published
- 2005
- Full Text
- View/download PDF
4. Increased risk of serious bacterial infections due to maternal immunosuppression in HIV-exposed uninfected infants in a European country
- Author
-
Marie Medus, Vincent Gajdos, Laure Clech, Céline Goissen, Arnaud Chalvon Demersay, Virginie Zarouk, Louis Bernard, Pierre-François Ceccaldi, René-Charles Rudigoz, Patricia Murger, Philippe Le Moine, Catherine Chirouze, Mandovi Rajguru, Ludovic Cravello, Véronique Lefevre Elbert, Luminata Shneider, Guy Leverger, Tessa Goetghebuer, Kamila Kebaili, Eliane Galiba, Claudine Touboul, Françoise Meier, Didier Tardif, Dieudoné Ekoukou, Michèle Granier, Ahmed Zakaria, Corinne Cudeville, Laurence Benoist, Emilie Piet, Emmanuelle Vintejoux, Yves Hatchuel, Christophe Michau, Jean-Luc Schmidt, Michel Françoise, Claire Briandet, Stéphane Blanche, Philippe Bailly-Salin, Anne Vanderbergh, Jeanne Sibiude, Christiane Kommé, Benoît Martha, Camille Runel-Belliard, Claire Pluchart, Imad Nahri, Vincent Jeantils, François Hervé, Isabelle Hau, Agnès Lefort, Dominique Ayral, Delphine Peretti, Stéphanie Proust, Marie Belloy, Christine Rouzioux, Arnaud Boutet, Philippe Van de Perre, Elisabeth Broustal, Cécile Hafner Mauvais, Thierry Pistone, Marie-Dominique Tabone, Hélène Dauphin, Laurent Cotte, Clement Taron-Brocard, Jean-Marie Lang, Christine Boissinot, Antoine Doumet, André Bongain, Narcisse Elenga, Geneviève Mouchnino, Anne Boutemy, Christine Cheneau, Pascale Perfezou, Pierre Frange, Mathilde Niault, Christelle Dupre, Anne Chacé, Jean-Paul Teglas, Corinne Daniel, Sophie Matheron, Severine Ansart, Martine Levine, Fabienne Caby, Marc Duval-Arnould, Isabelle Metheron, Kareen Billiemaz, Albert Faye, Didier Armangaud, Yamina Hammou, Neila Elaoun, Anne Deville, Philippe Arsac, Lydie Sanchez, Odile Luycx Vaillant, Philippe Lumbroso, Marie-Gisèle Lebrette, Norbert Winer, Elise Maurel, Ramona Abrudan, Luc De Saint Martin, Françoise Jacquier, Christian Calvez, Fabrice Monpoux, Louis Mesnard, Marie-Aude Khuong-Josses, David Rey, Isabelle Belzic, Christine Allisy, Claire Genet, Hervé Seaume, Roland Tubiana, Jacques Reynes, Pascale Nau, Gilles Blondin, Eric Lachassine, Yves Poinsignon, Cédric Arvieux, Leila Karaoui, Anaïs Perilhou, Amélie Benbara, Marine Joras, Sophie Leautez-Nainville, Sophie Ducroix-Roubert, Raghad Moalim, Pascal Bolot, Jacques Gaillat, Olivier Bollengier Stragier, Alain Devidas, Muriel Lalande, Delphine Lemercier, Jean-Pierre Brossier, Emmanuelle Boutard, Isolde Pauly-Ravelly, Marie-Françoise Le Coz, Anne Grelier, Alain Alissa, Christiane De Gennes, Jean-Luc Delassus, Emmanuel Mortier, Faiza Ajana, Ghislaine Firtion, Alain Berrebi, Rose Nguyen, Sarah Ducrocq, Jean-Marc Chamouilli, Fabienne Mazy, Maïa Banigé, Khaled Mohamed, Natacha Entz-Werle, Jacques Brouard, Germaine Bachelard, Sandrine Delmas, Anne Constanty, Véronique Reliquet, Sophie Couderc, Florence Veber, Lahcene Allal, Catherine Crenn-Hebert, Blandine Muanza, Gaelle Pinto-Cardoso, Laurent Mandelbrot, Ama Johnson, Fabienne Messaoudi, Christian Burle, Josiane Warszawski, Bénédicte Carpentier, Dominique Brault, Suzanne Braig, Pascale Fialaire, Corinne Fourcade, Elisabeth Questiaux, Véronique Chambrin, Alain Lafeuillade, Véronique Hentgen, Yves Aubrard, Anne Borgne, Sandrine-Anne Martha, Evelyne Werner, Corinne Floch-Tudal, Agnès Bourgeois Moine, Corinne Routier, Jérôme Le Chenadec, Anne Coursol, Alain Fisher, Amélie Chabrol, Cécile Winter, Cécile Brunet-Cartier, Philippe Labrune, Claudine Cayla, Françoise Mazingue, Virginie Vitrat, Cyril Clavel, Michel Segondy, Ruxandra-Oana Calin, Lise Selleret, Pierre Weinbreck, Zaitoun Abdallah Moussa, Joël Gaudelus, Gaetane Mousset, Thomas Guimard, Agnès Villemant Uludag, Emmanuelle Pannier, Brigitte Clavier, Nicole Ciraru-Vigneron, Alain Checoury, Christophe Elleau, Manuela Bonmarchand, Catherine Dollfus, Joëlle Dendale-Nguyen, Adrien May, Pierre Chevojon, Claire Hubert, Constance Borie, Marialuisa Partisani, Elie Azria, Edouard Vaucel, Erianna Bellaton Marouts, Philippe Moreau, Jean-Luc Esnault, Mahfoud Rouha, Mary-France Courcoux, Brigitte Heller-Roussin, Gilles Hittinger, Christine Rouger, Lanto Ratsimbazafy, Jean-Marc Labaune, Mohamed Abdelhadi, Brigitte Elharrar, Joëlle Tricoire, Eric David, Hassan Safwan, Karine Guimard, Bruno Carbonne, Muriel Barat, Marion Dehlinger-Paul, Stéphane Bounan, Myriam Costa, Estelle Bauville, Didier Pinquier, Valérie Garrait, Etienne Dienga, Odile Launay, Zoha Maakroun, and Dominique Salmon Ceron
- Subjects
Microbiology (medical) ,Pediatrics ,medicine.medical_specialty ,medicine.medical_treatment ,Human immunodeficiency virus (HIV) ,HIV Infections ,Kaplan-Meier Estimate ,medicine.disease_cause ,Infant, Newborn, Diseases ,Pregnancy ,medicine ,Humans ,Pregnancy Complications, Infectious ,Retrospective Studies ,business.industry ,Proportional hazards model ,Risk of infection ,Hazard ratio ,Infant, Newborn ,Infant ,Immunosuppression ,Bacterial Infections ,medicine.disease ,Confidence interval ,Infectious Disease Transmission, Vertical ,CD4 Lymphocyte Count ,Infectious Diseases ,Immunology ,Cohort ,Female ,France ,business ,Immunosuppressive Agents - Abstract
BACKGROUND Morbidity and mortality are higher among human immunodeficiency virus (HIV) exposed but uninfected (HEU) infants than unexposed infants, particularly if the mother had a low CD4 count. We investigated the possible association between maternal immune depression during pregnancy and the risk of infection in HEU infants in the national French Perinatal Cohort (EPF). METHODS All neonates, born alive, to HIV-1-infected women enrolled in the EPF between 2002 and 2010 were included. The primary outcome was the first serious (hospitalization or death) infection during the first year of life. The main exposure variable was maternal CD4 cell count near delivery. The Kaplan-Meier method and multivariate Cox models were applied, with the different types of infections managed as competing events. RESULTS Among 7638 HEU neonates, 699 had at least 1 serious infection (of which 159 were bacterial) with a Kaplan-Meier probability of 9.3% (95% confidence interval, 8.7-10.0) at 1 year. The risk of serious bacterial infection during the first year of life significantly increased with lower maternal CD4 cell count, before and after adjustment for maternal CD4 cell count
- Published
- 2014
5. Neurodevelopmental evaluation of 9-month-old infants exposed to low levels of leadin utero: involvement of monoamine neurotransmitters
- Author
-
Hai-Wang Tang, Christine Boissinot, Dave Campagna, G. Hellier, Guy Huel, and Philippe Blot
- Subjects
medicine.medical_specialty ,Statistics as Topic ,Neuropsychological Tests ,Toxicology ,Serotonergic ,Nervous System ,Cohort Studies ,chemistry.chemical_compound ,Pregnancy ,Internal medicine ,medicine ,Humans ,Biogenic Monoamines ,Neurotransmitter ,Dopaminergic ,Homovanillic acid ,Neurotoxicity ,Infant ,Homovanillic Acid ,Hydroxyindoleacetic Acid ,Fetal Blood ,medicine.disease ,Lead Poisoning ,Monoamine neurotransmitter ,Endocrinology ,Lead ,chemistry ,In utero ,Prenatal Exposure Delayed Effects ,Cord blood ,Female - Abstract
The objective of this work is to investigate the neurotoxicty of low-level lead exposure in utero on infants and the possible involvement of dopaminergic and serotonergic neurotransmitters. The correlation analysis for cord blood lead level, the concentrations of dopamine metabolite homovanillic acid (HVA) and serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in cord plasma and the neurodevelopmental scales of infants were conducted on 244 9-month-old children. Both score of sociability subscale and 5-HIAA concentration were correlated with cord blood lead level. The sociability score was negatively correlated with the concentration of HVA, whereas both the coordination score and the global score were negatively correlated with the concentration of 5-HIAA. With partial correlation analysis, after taking HVA into account, the significant negative correlation between the sociability score and the cord blood lead level that existed in the linear correlation analysis disappeared, and the score of global scale correlated negatively with lead level in cord blood. When taking 5-HIAA into account, the scores of all the neurodevelopmental subscales except the language subscale were significantly negatively correlated with lead level in cord blood. The results indicated that low-level lead exposure in utero could produce a neurotoxic effect on the developing serotonergic system in infants. The neurotoxicity of low-level lead exposure in utero may affect the sociability of infants. Serotonergic activity was shown to have a potential effect on neurodevelopmental assessment. It may interfere with the association between low-level lead exposure in utero and other neurodevelopmental performances of 9-month-old children.
- Published
- 1999
- Full Text
- View/download PDF
6. Surveillance de fin de grossesse
- Author
-
Claire Bossu, Brigitte Minette, Christine Boissinot, Olivier Sibony, and Philippe Blot
- Subjects
General Medicine - Published
- 1997
- Full Text
- View/download PDF
7. [Dealing with a 'different' child in the delivery room]
- Author
-
Dominique, Vernier and Christine, Boissinot
- Subjects
Parents ,Pregnancy ,Professional-Family Relations ,Delivery Rooms ,Prenatal Diagnosis ,Infant, Newborn ,Humans ,Abortion, Induced ,Female ,Congenital Abnormalities - Abstract
Maternity ward staff face complex situations, handling not only births, but sometimes also deaths. When a serious condition is revealed during the prenatal diagnosis, an abortion may be requested, but other parents choose to keep their disabled child. In such cases, healthcare professionals must support parents in learning about this "different" child.
- Published
- 2012
8. Excretion of ketoprofen and nalbuphine in human milk during treatment of maternal pain after delivery
- Author
-
Evelyne Jacqz-Aigrain, Christine Boissinot, M Popon, Oliver Sibony, R Serreau, Alain Sobel, and Jacqueline Michel
- Subjects
Ketoprofen ,Adult ,Nalbuphine ,Pain ,Excretion ,Pharmacokinetics ,Medicine ,Humans ,Pharmacology (medical) ,Postpartum pain ,Pharmacology ,medicine.diagnostic_test ,Milk, Human ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Postpartum Period ,Parturition ,Analgesics, Opioid ,Therapeutic drug monitoring ,Anesthesia ,Female ,business ,Breast feeding ,Postpartum period ,medicine.drug - Abstract
Analgesics are required to prevent and treat postpartum pain, but breast-feeding may be contraindicated, because data on milk transfer are very limited. The present study was undertaken to quantify the transfer of ketoprofen and nalbuphine in milk. Eighteen patients gave their informed consent to participate and completed the study. Following delivery, they received ketoprofen (100 mg/12 hours) and nalbuphine (0.2 mg/kg/4 hours) as an intravenous bolus over 2 to 3 days for postpartum pain. Milk samples were collected during the 12 hours between the third and fourth ketoprofen administrations. Ketoprofen and nalbuphine concentrations were determined with high-performance liquid chromatography. The mean and maximum ketoprofen milk concentrations were 57+/-37 and 91+/-51 ng/mL, respectively. Assuming a milk volume of 150 mL/kg/day, the mean and maximum doses that a breast-fed neonate would ingest during one day are 8.5+/-5.5 and 13.6+/-7.6 microg/kg/day, respectively, and the relative infant dose is 0.31+/-0.17% of the weight-adjusted maternal daily dose. The mean and maximum nalbuphine milk concentrations were 42+/-26 and 61+/-26 ng/mL, respectively. Assuming a milk volume of 150 mL/kg/day, the mean and maximum doses that a breast-fed neonate would ingest during one day is 7.0+/-3.2 and 9.0+/-3.8 microg/kg/day, and the relative infant dose is 0.59+/-0.27% of the weight-adjusted maternal daily dose. Therefore, breast-feeding is permissible when ketoprofen and/or nalbuphine are administered to the mother to treat postpartum pain.
- Published
- 2007
9. Biochemical investigation of foetal and neonatal thyroid function using the ACS-180SE analyser: clinical application
- Author
-
Michel Polak, Jean Guibourdenche, Didier Chevenne, Dominique Luton, Edith Vuillard, Christine Boissinot, Jean Luc Voluménie, Michèle Noël, and Dominique Porquet
- Subjects
Male ,endocrine system ,030213 general clinical medicine ,medicine.medical_specialty ,Goiter ,endocrine system diseases ,Clinical Biochemistry ,Thyroid Gland ,Thyrotropin ,030209 endocrinology & metabolism ,Gestational Age ,Hyperthyroidism ,03 medical and health sciences ,0302 clinical medicine ,Fetus ,Thyroid-stimulating hormone ,Hypothyroidism ,Pregnancy ,Reference Values ,Internal medicine ,Medicine ,Humans ,business.industry ,Thyroid ,Infant, Newborn ,Gestational age ,General Medicine ,medicine.disease ,Fetal Blood ,Thyroxine ,Endocrinology ,medicine.anatomical_structure ,Linear Models ,Gestation ,Triiodothyronine ,Female ,Thyroid function ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
Despite sonographic detection of foetal goitre, uncertainty persists in the initial diagnosis of thyrotoxicosis and hypothyroidism. The aim of this study was to establish foetal and neonatal iodothyronine and thyrotrophin reference values for the ACS-180SE analyser. From 22 to 36 weeks of gestation, median foetal serum free thyroxine (FT4) levels increased from 6·0 pmol/L to 14·3 pmol/L, while free triiodothyronine (FT3) levels increased from 0·7 pmoI/L to 1·9 pmol/L and mean thyrotrophin (TSH) levels remained stable (10·2±3·8 mU/L; n=33). At birth, concentrations were independent of gender and gestational age. Among the 10 cases of sonographically detected foetal goitre, serum TSH and FT4 were measured in five, showing hypothyroidism (3/5) or hyperthyroidism (2/5). Cord blood TSH levels reflected the efficacy of prenatal therapy. Measurement of foetal FT4 and TSH can be used to confirm foetal thyroid dysfunction, whereas treatment efficacy can be assessed sonographically and confirmed by measurement of TSH assay at birth.
- Published
- 2001
10. Diet or medically treated gestational diabetes: is there any difference for obstetrical and neonatal complications? A French cohort study
- Author
-
Blachier, Audrey, primary, Alberti, Corinne, additional, Korb, Diane, additional, Schmitz, Thomas, additional, Patrick, Vexiau, additional, Christine, Boissinot, additional, Oury, Jean-François, additional, and Sibony, Olivier, additional
- Published
- 2013
- Full Text
- View/download PDF
11. Arbitrarily primed polymerase chain reaction provides rapid differentiation of Proteus mirabilis isolates from a pediatric hospital
- Author
-
Edouard Bingen, Blot P, Jacques Elion, Hélène Cavé, Lambert-Zechovsky N, Naima Brahimi, Christine Boissinot, Desjardins P, and Erick Denamur
- Subjects
Microbiology (medical) ,DNA, Bacterial ,Paris ,Biology ,Polymerase Chain Reaction ,law.invention ,Microbiology ,Disease Outbreaks ,Ribotyping ,law ,Pregnancy ,Humans ,Pregnancy Complications, Infectious ,Ribosomal DNA ,Maternal-Fetal Exchange ,Proteus mirabilis ,Polymerase chain reaction ,Proteus Infections ,Infant, Newborn ,Outbreak ,biology.organism_classification ,DNA Fingerprinting ,Bacterial Typing Techniques ,DNA profiling ,Female ,Restriction fragment length polymorphism ,Epidemiologic Methods ,Polymorphism, Restriction Fragment Length ,Research Article - Abstract
During a systematic survey, maternal carriage of Proteus mirabilis was found over a 25-day period in 18 pregnant women admitted to the delivery ward of our hospital maternity. Five neonates born to these mothers were found to be colonized with P. mirabilis. We report here on the use of DNA fingerprinting by the arbitrarily primed polymerase chain reaction technique (AP-PCR) for the epidemiological investigation of this sudden outbreak. This approach was compared with the analysis of restriction fragment length polymorphisms of ribosomal DNA regions (ribotyping). Results of the AP-PCR and of ribotyping were in complete agreement in showing the genetic unrelatedness of the isolates obtained from each mother. Moreover, the results showed mother-to-infant vertical transmission of P. mirabilis in the neonates. AP-PCR is a rapid and discriminative method which seems particularly well suited to the epidemiological study of P. mirabilis.
- Published
- 1993
12. Mother-to-infant vertical transmission and cross-colonization of Streptococcus pyogenes confirmed by DNA restriction fragment length polymorphism analysis
- Author
-
Jacques Elion, Lambert-Zechovsky N, Y. Aujard, Edouard Bingen, Philippe Blot, Erick Denamur, Christine Boissinot, and Naïna Brahimi
- Subjects
Adult ,DNA, Bacterial ,Streptococcus pyogenes ,Placenta ,Deoxyribonuclease HindIII ,Biology ,HindIII ,medicine.disease_cause ,DNA, Ribosomal ,Microbiology ,Ribotyping ,chemistry.chemical_compound ,Pregnancy ,Streptococcal Infections ,medicine ,Immunology and Allergy ,Humans ,Prospective Studies ,Pregnancy Complications, Infectious ,Serotyping ,Ribosomal DNA ,Genetics ,Cross Infection ,Stomach ,Infant, Newborn ,Ear ,Streptococcaceae ,biology.organism_classification ,Infectious Diseases ,chemistry ,Vagina ,biology.protein ,Female ,Restriction fragment length polymorphism ,Ethidium bromide ,DNA ,Polymorphism, Restriction Fragment Length - Abstract
Restriction fragment length polymorphism (RFLP) analysis of total DNA and of ribosomal DNA (rDNA) regions (ribotyping) were used to document Streptococcus pyogenes vertical mother-to-infant transmission and to investigate the spread of S. pyogenes in an obstetric unit. Two isolates from a newborn, two isolates from his mother (patient 1), and two isolates from two other mothers (patients 2 and 3) were studied. RFLP of total DNA, both after HindIII and PvuII digestions and ethidium bromide staining, gave indistinguishable patterns for the strains isolated from the neonate, his mother, and patient 2. Strains from patient 3 and six unrelated strains studied for comparison showed different patterns. In our system, ribotyping was less discriminative than total DNA RFLP analysis. DNA RFLP analysis therefore provides a valuable molecular tool for studying S. pyogenes epidemiology.
- Published
- 1992
13. Neurodevelopmental evaluation of 9-month-old infants exposed to low levels of lead in utero: involvement of monoamine neurotransmitters.
- Author
-
Hai-Wang Tang, Guy Huel, Dave Campagna, Georgette Hellier, Christine Boissinot, and Philippe Blot
- Subjects
HOMOVANILLIC acid ,STATISTICAL correlation ,CORD blood ,NEUROTRANSMITTERS - Abstract
The objective of this work is to investigate the neurotoxicty of low-level lead exposure in utero on infants and the possible involvement of dopaminergic and serotonergic neurotransmitters. The correlation analysis for cord blood lead level, the concentrations of dopamine metabolite homovanillic acid (HVA) and serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in cord plasma and the neurodevelopmental scales of infants were conducted on 244 9-month-old children. Both score of sociability subscale and 5-HIAA concentration were correlated with cord blood lead level. The sociability score was negatively correlated with the concentration of HVA, whereas both the coordination score and the global score were negatively correlated with the concentration of 5-HIAA. With partial correlation analysis, after taking HVA into account, the significant negative correlation between the sociability score and the cord blood lead level that existed in the linear correlation analysis disappeared, and the score of global scale correlated negatively with lead level in cord blood. When taking 5-HIAA into account, the scores of all the neurodevelopmental subscales except the language subscale were significantly negatively correlated with lead level in cord blood. The results indicated that low-level lead exposure in utero could produce a neurotoxic effect on the developing serotonergic system in infants. The neurotoxicity of low-level lead exposure in utero may affect the sociability of infants. Serotonergic activity was shown to have a potential effect on neurodevelopmental assessment. It may interfere with the association between low-level lead exposure in utero and other neurodevelopmental performances of 9-month-old children. Copyright © 1999 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.